DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share

Note 11 - Net Loss Per Share

9 Months Ended

Sep. 30, 2020

Net Loss Per Share

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):

	Three Months Ended September 30,						Nine M onths Ended September 30,
	2020			2019			2020			2019
Net loss	$	(3,193	)	$	(2,448	)	$	(8,092	)	$	(8,169	)
Weighted average shares outstanding—basic and diluted		16,689,074			12,006,874			14,652,749			11,981,233
Basic and diluted net loss per share	$	(0.19	)	$	(0.20	)	$	(0.55	)	$	(0.68	)

The following outstanding potential common shares were

not

included in the diluted net loss per share calculations as their effects were

not

dilutive:

	Three Months Ended September 30,				Nine M onths Ended September 30,
	2020		201 9		2020		201 9
Employee and non-employee stock options		1,395,399		1,251,893		1,395,399		1,251,893
Common shares issuable under common share purchase warrants		265,000		807,563		265,000		807,563
Common shares issuable under deferred unit awards		47,237		21,183		47,237		21,183